Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Cancer Cell 2015 Jan 11;27(1):85-96. Epub 2014 Dec 11.

Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK. Electronic address:

BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) signaling or mutant NRAS, which drive paradoxical reactivation of the pathway. We describe pan-RAF inhibitors (CCT196969, CCT241161) that also inhibit SFKs. These compounds do not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma. They inhibit melanoma cells and patient-derived xenografts that are resistant to BRAF and BRAF/MEK inhibitors. Thus, paradox-breaking pan-RAF inhibitors that also inhibit SFKs could provide first-line treatment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistance.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2014.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297292PMC
January 2015

Publication Analysis

Top Keywords

mutant melanoma
12
nras mutant
8
braf mutant
8
braf nras
8
drive paradoxical
8
pan-raf inhibitors
8
inhibit sfks
8
braf
6
mutant
5
inhibitors
5
kinase sfk
4
xenografts resistant
4
patient-derived xenografts
4
paradoxical pathway
4
sfk signaling
4
pathway reactivation
4
rtk/src-family kinase
4
signaling mutant
4
resistant braf
4
reactivation receptor
4

Similar Publications